Viridian Therapeutics
VRDN
23 hedge funds and large institutions have $4.3M invested in Viridian Therapeutics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.48% less ownership
Funds ownership: 2.33% → 1.85% (-0.48%)
30% less funds holding
Funds holding: 33 → 23 (-10)
46% less capital invested
Capital invested by funds: $7.95M → $4.3M (-$3.65M)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$178K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$60.3K |
| 3 |
VF
Virtu Financial
New York
|
+$35.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$1.01M |
| 2 |
Goldman Sachs
New York
|
-$152K |
| 3 |
Millennium Management
New York
|
-$151K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$150K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SAM
26
Seelaus Asset Management
Chatham,
New Jersey
| – | -$13K | -1,145 | Closed |
|
27
D.E. Shaw & Co
New York
| – | -$12K | -1,127 | Closed |
|
|
LP
28
LMR Partners
London,
United Kingdom
| – | -$11K | -989 | Closed |
|
|
ACA
29
Atlas Capital Advisors
Jackson,
Wyoming
| – | -$9.42K | -859 | Closed |
|
30
HighTower Advisors
Chicago,
Illinois
| – | -$10K | -814 | Closed |
|
31
Morgan Stanley
New York
| – | -$9K | -800 | Closed |
|
32
Victory Capital Management
San Antonio,
Texas
| – | -$3K | -264 | Closed |
|
VRDN Hedge Fund Activity: Q4 2019 in Review
23 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2019, worth a combined $4.3M — down 46% from $7.95M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of VRDN and 3 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $178K. The largest seller was 683 Capital Management, cutting an estimated $1.01M.
- 23 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2019, down from 33 in Q3 2019.
- Funds reported $4.3M of Viridian Therapeutics stock for Q4 2019, down 46% quarter-over-quarter.
- 3 funds opened new Viridian Therapeutics positions in Q4 2019 and 12 closed out, a net change of -9 holders.
- The largest Viridian Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $178K added.
- The largest Viridian Therapeutics seller in Q4 2019 was 683 Capital Management, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2019.